AdvaMed Dx
This article was originally published in The Gray Sheet
Executive Summary
Diagnostics firms bioMerieux, Gen-Probe and Quidel recently joined AdvaMed's newly formed in-vitro-diagnostics-focused AdvaMed Dx division (1"The Gray Sheet" Dec. 21, 2009). Each of the companies had been in AdavMed at one time, but had let their memberships lapse
You may also be interested in...
AdvaMed Begets "AdvaMed Dx" For IVD-Focused Lobbying Effort
AdvaMed is forming an "association within an association" to focus exclusively on in vitro diagnostics, the group announced Dec. 17
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.